{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:36:24Z","timestamp":1791203784736,"version":"4.2.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,5,15]],"date-time":"2015-05-15T00:00:00Z","timestamp":1431648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,5,15]],"date-time":"2015-05-15T00:00:00Z","timestamp":1431648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1038\/leu.2015.140","type":"journal-article","created":{"date-parts":[[2015,6,15]],"date-time":"2015-06-15T06:41:15Z","timestamp":1434350475000},"page":"580-593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1"],"prefix":"10.1038","volume":"30","author":[{"given":"A E","family":"Teo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R N","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L J","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,15]]},"reference":[{"key":"BFleu2015140_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.coi.2006.01.007","volume":"18","author":"J Hagman","year":"2006","unstructured":"Hagman J, Lukin K . Transcription factors drive B cell development. Curr Opin Immunol 2006; 18: 127\u2013134.","journal-title":"Curr Opin Immunol"},{"key":"BFleu2015140_CR2","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1101\/gad.7.10.2048","volume":"7","author":"T Czerny","year":"1993","unstructured":"Czerny T, Schaffner G, Busslinger M . DNA sequence recognition by Pax proteins: bipartite structure of the paired domain and its binding site. Genes Dev 1993; 7: 2048\u20132061.","journal-title":"Genes Dev"},{"key":"BFleu2015140_CR3","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1002\/j.1460-2075.1996.tb00548.x","volume":"15","author":"P Dorfler","year":"1996","unstructured":"Dorfler P, Busslinger M . C-terminal activating and inhibitory domains determine the transactivation potential of BSAP (Pax-5), Pax-2 and Pax-8. EMBO J 1996; 15: 1971\u20131982.","journal-title":"EMBO J"},{"key":"BFleu2015140_CR4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/ni1454","volume":"8","author":"C Cobaleda","year":"2007","unstructured":"Cobaleda C, Schebesta A, Delogu A, Busslinger M . Pax5: the guardian of B cell identity and function. Nat Immunol 2007; 8: 463\u2013470.","journal-title":"Nat Immunol"},{"key":"BFleu2015140_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/44076","volume":"401","author":"SL Nutt","year":"1999","unstructured":"Nutt SL, Heavey B, Rolink AG, Busslinger M . Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 1999; 401: 556\u2013562.","journal-title":"Nature"},{"key":"BFleu2015140_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.immuni.2006.01.012","volume":"24","author":"A Delogu","year":"2006","unstructured":"Delogu A, Schebesta A, Sun Q, Aschenbrenner K, Perlot T, Busslinger M . Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity 2006; 24: 269\u2013281.","journal-title":"Immunity"},{"key":"BFleu2015140_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1126\/science.1067518","volume":"297","author":"I Mikkola","year":"2002","unstructured":"Mikkola I, Heavey B, Horcher M, Busslinger M . Reversion of B cell commitment upon loss of Pax5 expression. Science 2002; 297: 110\u2013113.","journal-title":"Science"},{"key":"BFleu2015140_CR8","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1182\/blood.V99.2.472","volume":"99","author":"C Schaniel","year":"2002","unstructured":"Schaniel C, Bruno L, Melchers F, Rolink AG . Multiple hematopoietic cell lineages develop in vivo from transplanted Pax5-deficient pre-B I-cell clones. Blood 2002; 99: 472\u2013478.","journal-title":"Blood"},{"key":"BFleu2015140_CR9","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.4049\/jimmunol.173.6.3935","volume":"173","author":"S Hoflinger","year":"2004","unstructured":"Hoflinger S, Kesavan K, Fuxa M, Hutter C, Heavey B, Radtke F et al. Analysis of Notch1 function by in vitro T cell differentiation of Pax5 mutant lymphoid progenitors. J Immunol 2004; 173: 3935\u20133944.","journal-title":"J Immunol"},{"key":"BFleu2015140_CR10","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood.V92.10.3865","volume":"92","author":"AM Morrison","year":"1998","unstructured":"Morrison AM, Jager U, Chott A, Schebesta M, Haas OA, Busslinger M . Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma. Blood 1998; 92: 3865\u20133878.","journal-title":"Blood"},{"key":"BFleu2015140_CR11","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/nature05690","volume":"446","author":"CG Mullighan","year":"2007","unstructured":"Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758\u2013764.","journal-title":"Nature"},{"key":"BFleu2015140_CR12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nature06159","volume":"449","author":"C Cobaleda","year":"2007","unstructured":"Cobaleda C, Jochum W, Busslinger M . Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 2007; 449: 473\u2013477.","journal-title":"Nature"},{"key":"BFleu2015140_CR13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ajh.23176","volume":"87","author":"JM Vose","year":"2012","unstructured":"Vose JM . Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am J Hematol 2012; 87: 604\u2013609.","journal-title":"Am J Hematol"},{"key":"BFleu2015140_CR14","first-page":"11","volume":"91","author":"I Salaverria","year":"2006","unstructured":"Salaverria I, Perez-Galan P, Colomer D, Campo E . Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica 2006; 91: 11\u201316.","journal-title":"Haematologica"},{"key":"BFleu2015140_CR15","doi-asserted-by":"publisher","first-page":"5268","DOI":"10.1038\/sj.onc.1202997","volume":"18","author":"JM Adams","year":"1999","unstructured":"Adams JM, Harris AW, Strasser A, Ogilvy S, Cory S . Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector. Oncogene 1999; 18: 5268\u20135277.","journal-title":"Oncogene"},{"key":"BFleu2015140_CR16","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1002\/j.1460-2075.1994.tb06488.x","volume":"13","author":"SE Bodrug","year":"1994","unstructured":"Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM . Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 1994; 13: 2124\u20132130.","journal-title":"EMBO J"},{"key":"BFleu2015140_CR17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nature03097","volume":"432","author":"MB Kastan","year":"2004","unstructured":"Kastan MB, Bartek J . Cell-cycle checkpoints and cancer. Nature 2004; 432: 316\u2013323.","journal-title":"Nature"},{"key":"BFleu2015140_CR18","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.tibs.2005.09.005","volume":"30","author":"M Malumbres","year":"2005","unstructured":"Malumbres M, Barbacid M . Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005; 30: 630\u2013641.","journal-title":"Trends Biochem Sci"},{"key":"BFleu2015140_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature03094","volume":"432","author":"J Massague","year":"2004","unstructured":"Massague J . G1 cell-cycle control and cancer. Nature 2004; 432: 298\u2013306.","journal-title":"Nature"},{"key":"BFleu2015140_CR20","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1182\/blood.V88.10.4012.bloodjournal88104012","volume":"88","author":"M Chilosi","year":"1996","unstructured":"Chilosi M, Doglioni C, Magalini A, Inghirami G, Krampera M, Nadali G et al. p21\/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin\u2019s lymphomas: a potential marker of p53 tumor-suppressor gene function. Blood 1996; 88: 4012\u20134020.","journal-title":"Blood"},{"key":"BFleu2015140_CR21","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1182\/blood-2002-07-2009","volume":"101","author":"M Sanchez-Beato","year":"2003","unstructured":"Sanchez-Beato M, Sanchez-Aguilera A, Piris MA . Cell cycle deregulation in B-cell lymphomas. Blood 2003; 101: 1220\u20131235.","journal-title":"Blood"},{"key":"BFleu2015140_CR22","doi-asserted-by":"publisher","first-page":"8713","DOI":"10.1074\/jbc.M005248200","volume":"276","author":"BC Ding","year":"2001","unstructured":"Ding BC, Whetstine JR, Witt TL, Schuetz JD, Matherly LH . Repression of human reduced folate carrier gene expression by wild type p53. J Biol Chem 2001; 276: 8713\u20138719.","journal-title":"J Biol Chem"},{"key":"BFleu2015140_CR23","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/leu.2008.348","volume":"23","author":"E Drakos","year":"2009","unstructured":"Drakos E, Atsaves V, Li J, Leventaki V, Andreeff M, Medeiros LJ et al. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia 2009; 23: 784\u2013790.","journal-title":"Leukemia"},{"key":"BFleu2015140_CR24","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.4049\/jimmunol.180.3.1719","volume":"180","author":"C Pridans","year":"2008","unstructured":"Pridans C, Holmes ML, Polli M, Wettenhall JM, Dakic A, Corcoran LM et al. Identification of Pax5 target genes in early B cell differentiation. J Immunol 2008; 180: 1719\u20131728.","journal-title":"J Immunol"},{"key":"BFleu2015140_CR25","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","volume":"103","author":"W Matsui","year":"2004","unstructured":"Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103: 2332\u20132336.","journal-title":"Blood"},{"key":"BFleu2015140_CR26","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1182\/blood-2013-07-517136","volume":"123","author":"Z Chen","year":"2014","unstructured":"Chen Z, Orlowski RZ, Wang M, Kwak L, McCarty N . Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 2014; 123: 2204\u20132208.","journal-title":"Blood"},{"key":"BFleu2015140_CR27","doi-asserted-by":"publisher","first-page":"e61603","DOI":"10.1371\/journal.pone.0061603","volume":"8","author":"C Carlo-Stella","year":"2013","unstructured":"Carlo-Stella C, Locatelli SL, Giacomini A, Cleris L, Saba E, Righi M et al. Sorafenib inhibits lymphoma xenografts by targeting MAPK\/ERK and AKT pathways in tumor and vascular cells. PLoS One 2013; 8: e61603.","journal-title":"PLoS One"},{"key":"BFleu2015140_CR28","doi-asserted-by":"publisher","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","volume":"111","author":"J Dal Col","year":"2008","unstructured":"Dal Col J, Zancai P, Terrin L, Guidoboni M, Ponzoni M, Pavan A et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 2008; 111: 5142\u20135151.","journal-title":"Blood"},{"key":"BFleu2015140_CR29","doi-asserted-by":"publisher","first-page":"5622","DOI":"10.1182\/blood-2010-05-285866","volume":"116","author":"JB Dennison","year":"2010","unstructured":"Dennison JB, Shanmugam M, Ayres ML, Qian J, Krett NL, Medeiros LJ et al. 8-Aminoadenosine inhibits Akt\/mTOR and Erk signaling in mantle cell lymphoma. Blood 2010; 116: 5622\u20135630.","journal-title":"Blood"},{"key":"BFleu2015140_CR30","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.1158\/1078-0432.CCR-08-3215","volume":"15","author":"A Psyrri","year":"2009","unstructured":"Psyrri A, Papageorgiou S, Liakata E, Scorilas A, Rontogianni D, Kontos CK et al. Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res 2009; 15: 5724\u20135732.","journal-title":"Clin Cancer Res"},{"key":"BFleu2015140_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/path.2521","volume":"218","author":"M Wang","year":"2009","unstructured":"Wang M, Atayar C, Rosati S, Bosga-Bouwer A, Kluin P, Visser L . JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125. J Pathol 2009; 218: 95\u2013103.","journal-title":"J Pathol"},{"key":"BFleu2015140_CR32","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nrm1743","volume":"6","author":"W Kolch","year":"2005","unstructured":"Kolch W . Coordinating ERK\/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 2005; 6: 827\u2013837.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFleu2015140_CR33","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/ni1324","volume":"7","author":"AB Cooper","year":"2006","unstructured":"Cooper AB, Sawai CM, Sicinska E, Powers SE, Sicinski P, Clark MR et al. A unique function for cyclin D3 in early B cell development. Nat Immunol 2006; 7: 489\u2013497.","journal-title":"Nat Immunol"},{"key":"BFleu2015140_CR34","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/sj.leu.2403716","volume":"19","author":"S Nagel","year":"2005","unstructured":"Nagel S, Scherr M, Quentmeier H, Kaufmann M, Zaborski M, Drexler HG et al. HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3. Leukemia 2005; 19: 841\u2013846.","journal-title":"Leukemia"},{"key":"BFleu2015140_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1081\/IMM-120034231","volume":"33","author":"C Patil","year":"2004","unstructured":"Patil C, Zhu X, Rossa C Jr., Kim YJ, Kirkwood KL . p38 MAPK regulates IL-1beta induced IL-6 expression through mRNA stability in osteoblasts. Immunol Invest 2004; 33: 213\u2013233.","journal-title":"Immunol Invest"},{"key":"BFleu2015140_CR36","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1182\/blood-2012-04-424630","volume":"120","author":"L Zhang","year":"2012","unstructured":"Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW et al. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 2012; 120: 3783\u20133792.","journal-title":"Blood"},{"key":"BFleu2015140_CR37","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1182\/blood-2002-03-0844","volume":"100","author":"L Graf","year":"2002","unstructured":"Graf L, Iwata M, Torok-Storb B . Gene expression profiling of the functionally distinct human bone marrow stromal cell lines HS-5 and HS-27a. Blood 2002; 100: 1509\u20131511.","journal-title":"Blood"},{"key":"BFleu2015140_CR38","doi-asserted-by":"publisher","first-page":"16547","DOI":"10.1074\/jbc.M110629200","volume":"277","author":"NO Karpinich","year":"2002","unstructured":"Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL . The course of etoposide- induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem 2002; 277: 16547\u201316552.","journal-title":"J Biol Chem"},{"key":"BFleu2015140_CR39","doi-asserted-by":"publisher","first-page":"7339","DOI":"10.1074\/jbc.M110.191916","volume":"286","author":"SK Manna","year":"2011","unstructured":"Manna SK, Gangadharan C, Edupalli D, Raviprakash N, Navneetha T, Mahali S et al. Ras puts the brake on doxorubicin-mediated cell death in p53-expressing cells. J Biol Chem 2011; 286: 7339\u20137347.","journal-title":"J Biol Chem"},{"key":"BFleu2015140_CR40","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2217\/14796694.4.2.149","volume":"4","author":"KS Suh","year":"2008","unstructured":"Suh KS, Goy A . Bortezomib in mantle cell lymphoma. Future Oncol 2008; 4: 149\u2013168.","journal-title":"Future Oncol"},{"key":"BFleu2015140_CR41","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1182\/blood-2010-02-269514","volume":"117","author":"P Perez-Galan","year":"2011","unstructured":"Perez-Galan P, Mora-Jensen H, Weniger MA, Shaffer AL 3rd, Rizzatti EG, Chapman CM et al. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood 2011; 117: 542\u2013552.","journal-title":"Blood"},{"key":"BFleu2015140_CR42","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V89.6.2067","volume":"89","author":"LH Argatoff","year":"1997","unstructured":"Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD . Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997; 89: 2067\u20132078.","journal-title":"Blood"},{"key":"BFleu2015140_CR43","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/sj.leu.2402272","volume":"15","author":"M Bernard","year":"2001","unstructured":"Bernard M, Gressin R, Lefrere F, Drenou B, Branger B, Caulet-Maugendre S et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia 2001; 15: 1785\u20131791.","journal-title":"Leukemia"},{"key":"BFleu2015140_CR44","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","volume":"82","author":"F Bosch","year":"1998","unstructured":"Bosch F, Lopez-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82: 567\u2013575.","journal-title":"Cancer"},{"key":"BFleu2015140_CR45","volume-title":"HTS Assay Validation","author":"PW Iversen","year":"2004","unstructured":"Iversen PW, Beck B, Chen YF, Dere W, Devanarayan V, Eastwood BJ et al In: Sittampalam GS, Gal-Edd N, Arkin M, Auld D, Austin C, Bejcek B et al (eds). HTS Assay Validation. Assay Guidance Manual: : Bethesda, MD, 2004."},{"key":"BFleu2015140_CR46","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","volume":"3","author":"A Rosenwald","year":"2003","unstructured":"Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185\u2013197.","journal-title":"Cancer Cell"},{"key":"BFleu2015140_CR47","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1038\/nm.2966","volume":"18","author":"D Laimer","year":"2012","unstructured":"Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O et al. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med 2012; 18: 1699\u20131704.","journal-title":"Nat Med"},{"key":"BFleu2015140_CR48","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/sj.bjc.6604794","volume":"100","author":"M Colomiere","year":"2009","unstructured":"Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J et al. Cross talk of signals between EGFR and IL-6R through JAK2\/STAT3 mediate epithelial- mesenchymal transition in ovarian carcinomas. Br J Cancer 2009; 100: 134\u2013144.","journal-title":"Br J Cancer"},{"key":"BFleu2015140_CR49","doi-asserted-by":"publisher","first-page":"16975","DOI":"10.1073\/pnas.1315862110","volume":"110","author":"Y Wang","year":"2013","unstructured":"Wang Y, van Boxel-Dezaire AH, Cheon H, Yang J, Stark GR . STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. Proc Natl Acad Sci USA 2013; 110: 16975\u201316980.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2015140_CR50","doi-asserted-by":"publisher","first-page":"e3794","DOI":"10.1371\/journal.pone.0003794","volume":"3","author":"E Wu","year":"2008","unstructured":"Wu E, Palmer N, Tian Z, Moseman AP, Galdzicki M, Wang X et al. Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One 2008; 3: e3794.","journal-title":"PLoS One"},{"key":"BFleu2015140_CR51","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1158\/0008-5472.CAN-04-3589","volume":"65","author":"DR Hodge","year":"2005","unstructured":"Hodge DR, Peng B, Cherry JC, Hurt EM, Fox SD, Kelley JA et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 2005; 65: 4673\u20134682.","journal-title":"Cancer Res"},{"key":"BFleu2015140_CR52","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cell.2009.12.007","volume":"140","author":"S Pece","year":"2010","unstructured":"Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010; 140: 62\u201373.","journal-title":"Cell"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2015140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015140","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:12:24Z","timestamp":1648743144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,15]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["BFleu2015140"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.140","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,15]]},"assertion":[{"value":"4 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}